Username Password
About People & Picks | Help | Sign up
Home My P&P People Picks Tops Blogs Groups
S&P 500: 1,317.11 Change: -0.21%
TheHammer
TheHammer
P&P Score: 0.61   Points: -255.76   Accuracy: 41.67%   Average Pick Score: -33.11   Annual Return: 64.39% (87.68% since 1/15/11)  

TheHammer's Blog : DNDN-all fluff or the real deal?

Date January 7, 2011    Comments Comments (3)    Rate this post Recommend This Post (89)   
Bookmark and Share
Abuse this post  Report Abuse
Please report this as abuse only if you believe it violates People And Picks  Terms of Use
You must log in to send an abuse report.
Share ThisShare This
Dendreon (DNDN)- this biotech points to the future of personalized medicine, specifically tailoring your immune cells to fight diseases. The personalization of medicine will likely reduce side effects, so this could be the next big thing in medicine.

Dendreon's has only one real drug now called Provenge. the drug is super expensive ($93k for 3 treatments).projected sales of Provenge are reported to be about $400 million, so there is a good market. Dendreon will aso begin testing a bladder cancer drug.

Note that Fidelity has staken a huge stake of 13% in the company and George Soros reportedly owns shares. So there are some great holders here.

At $5.5 billion market cap, is this going to be a multibagger or dead money?

Tags : DNDN  

3 Comment(s):

Author MightyMo     Date January 9, 2011 17:05  Edited: January 9, 2011 by MightyMo Abuse this post Report Abuse
Please report this as abuse only if you believe it violates People And Picks  Terms of Use
You must log in to send an abuse report.
DNDN has been a battlefield stock since it uses an approved immunization method instead of radiation or chemotheraphy methods as a treatment for cancer.
There is more demand than supply. It is also time sensitive. A patient has to get his DNA cells from his body to the manufacturing plans and processed and delievered back and inserted back into the patient in a certain timeframe. Thus the location of the plants are important. DNDN provenge is currently produced at 100% capacity. DNDN will have two new plants in production towards the end of the year. It also announced building one in Europe. You are correct, DNDN said it expects to bring in 400 million this year, up from 48 million in 2010. Analysts are saying about 700-800 million in 2011, and 1-3 billion thereafter. It's not out of reason to consider this stock as a multi-bagger winner.
Author TheHammer     Date January 10, 2011 22:56 Abuse this post Report Abuse
Please report this as abuse only if you believe it violates People And Picks  Terms of Use
You must log in to send an abuse report.
MightyMo, any idea about Neuvenge, the bladder cancer drug? can the same factories be used to produce other drugs?
Author PrimoTenore     Date January 11, 2011 09:58 Abuse this post Report Abuse
Please report this as abuse only if you believe it violates People And Picks  Terms of Use
You must log in to send an abuse report.
That's a hefty price tag for Provenge when it only buys you an extra 4 months. Hard to believe it will be covered by Medicare.
Want to comment on this post? Sign up now. It's FREE!
Already registered? Log In.
Sponsored Links
©2008-2012 PeopleAndPicks.com | Terms of Use